dramatically accelerate vaccination. Available evidence on efficacy is not dispositive but suggests half- or even quarter-doses of …

vaccination and reduce mortality, and that the costs of testing these regimens are dwarfed by their potential benefits. We first … use an SEIR model to estimate that under these efficacy levels, doubling or quadrupling the rate of vaccination by using … vaccination campaigns based on existing immune response data, as some did for delayed second doses. If efficacy turned out to be …

vaccination and reduce mortality, and that the costs of testing these regimens are dwarfed by their potential benefits. We first … use an SEIR model to estimate that under these efficacy levels, doubling or quadrupling the rate of vaccination by using … vaccination campaigns based on existing immune response data, as some did for delayed second doses. If efficacy turned out to be …